AC Immune’s (NASDAQ:ACIU) lock-up period is set to end on Wednesday, March 22nd. AC Immune had issued 6,000,000 shares in its IPO on September 23rd. The total size of the offering was $66,000,000 based on an initial share price of $11.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
A number of research firms recently commented on ACIU. Credit Suisse Group AG reiterated an “outperform” rating and set a $18.00 price target on shares of AC Immune in a report on Tuesday, December 13th. Jefferies Group LLC reiterated a “buy” rating and set a $25.00 price target on shares of AC Immune in a report on Tuesday, December 13th. Zacks Investment Research upgraded AC Immune from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, January 3rd. Finally, Leerink Swann reiterated an “outperform” rating on shares of AC Immune in a report on Saturday, November 26th.
Your IP Address:
Shares of AC Immune (NASDAQ:ACIU) opened at 11.55 on Tuesday. AC Immune has a one year low of $10.36 and a one year high of $19.97. The stock’s 50 day moving average price is $12.20 and its 200-day moving average price is $13.42. The company’s market cap is $572.22 million.
Institutional investors have recently made changes to their positions in the stock. FMR LLC raised its position in shares of AC Immune by 13.4% in the fourth quarter. FMR LLC now owns 3,637,402 shares of the company’s stock valued at $46,344,000 after buying an additional 428,815 shares in the last quarter. Artal Group S.A. raised its position in shares of AC Immune by 66.7% in the fourth quarter. Artal Group S.A. now owns 250,000 shares of the company’s stock valued at $3,245,000 after buying an additional 100,000 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of AC Immune during the fourth quarter valued at $457,000. Hedge funds and other institutional investors own 14.39% of the company’s stock.
About AC Immune
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
Receive News & Ratings for AC Immune Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune Ltd and related companies with MarketBeat.com's FREE daily email newsletter.